Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.56 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882052 | 0.97 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3874124 | 0.96 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3875375 | 0.94 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3875146 | 0.93 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3876106 | 0.93 | PTK2 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3880829 | 0.91 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3876485 | 0.91 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3875990 | 0.90 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3995146 | 0.90 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3876088 | 0.89 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | MAPK14 26/4885MAPK13 44/4885MAPK12 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.